THE US Food and Drug Administration approved Pfizer’s gene therapy for hemophilia B on Friday (Apr 26), the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein.
People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, which can cause spontaneous as well as severe bleeding following injuries or surgery. It predominately affects males.
Pfizer’s one-time therapy, branded as Beqvez, is designed to stimulate production of the protein, called factor IX (FIX), by the patient’s own body instead of intravenous infusions of FIX multiple times a week or a month.
A single dose of Pfizer’s therapy was shown to work as well as standard-of-care protein infusions after a year, with bleeding completely eliminated in 60 per cent of patients versus 29 per cent who received infusions.
The therapy will be available by prescription to eligible patients this quarter, a company spokesperson said, adding the list price of the therapy would be US$3.5 million in the US.
Hemophilia B is estimated to affect nearly four in every 100,000 US males, while related disorder hemophilia A is estimated to affect 12 in every 100,000 US males, according to government data. REUTERS
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
